STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs

Article excerpt

ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.  The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.  Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.   Continue to STAT+ to read the full story…